Artificial Intelligence stands to revolutionize drug discovery and manufacturing in the biotech industry, promising faster, cost-effective processes, which could greatly benefit biotech investors. The ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to continue.

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Monday. So, we’ve got a welcome bump in the XBI, see that European ...

The Biotechnology sector is known to carry inherent risks as the stock price of a company in this sector can vary wildly based on the outcomes of clinical trials of drugs and regulatory interventions.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006. Retail ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at biotech’s latest nadir, the ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. The ETF industry has ...